Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych VivasGeneral adult psychiatry — anxiety disorders

Psych Vivas · General adult psychiatry — anxiety disorders

Panic disorder and agoraphobia — structured clinical viva

Fellowship viva covering severe panic with agoraphobia, pseudo-resistance, SSRI re-trial dosing, CBT exposure, benzodiazepine discontinuation with CBT, and inappropriate ECT expectations.

clinical
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
You are the psychiatry registrar. A 41-year-old man with 3 years of panic disorder and progressive agoraphobia is housebound most days. He takes diazepam 5 mg three times daily from his GP for 18 months, tried sertraline 50 mg for 10 days two years ago 'but felt worse,' and declined psychology. His partner asks whether 'stronger tranquilisers' or 'shock treatment' are next. Discuss formulation, why prior SSRI trial was inadequate, your pharmacological and CBT plan, benzodiazepine taper strategy, and what you would say about ECT.

Interpretation

Reveal interpretation

This is severe panic disorder with agoraphobia and chronic benzodiazepine use, with pseudo-resistance to an inadequate SSRI trial (50 mg for only 10 days — neither dose nor duration sufficient, and early activation may have been mislabelled as failure). ECT is not indicated for uncomplicated panic/agoraphobia and should be gently corrected if the partner equates it with "stronger treatment for anxiety."[1][4]

Formulation. Vulnerability (anxiety sensitivity), precipitants (first unexpected attacks), maintaining factors (avoidance, safety behaviours, diazepam as safety signal, no exposure therapy), and functional collapse (housebound). Assess depression/suicide risk, substances, and medical differentials as always.[4]

Plan. Collaborative psychoeducation; high-quality CBT with interoceptive and graded situational exposure (home-based/outreach if needed initially); restart SSRI carefully — e.g. sertraline 25 mg then 50 mg with slow titration toward a therapeutic range with early review for activation; do not escalate to "stronger tranquilisers" as definitive care.[1][3][4]

Benzodiazepine. Agree a slow supervised taper, convert to a longer-acting agent if appropriate under local practice, and pair with CBT techniques shown to aid benzodiazepine discontinuation in panic.[2]

Communication. Empathise with the partner's desperation; explain evidence hierarchy (CBT + SSRI/SNRI); set functional goals (leaving house, short trips); book early review; safety-net depression/suicide.[4]

Key points

10 days of sertraline 50 mg is not an adequate trial

Early activation is common; re-try with lower start, slower titration, support, and full duration at therapeutic dose.

Chronic benzodiazepines are not definitive panic care

Taper with CBT support; do not escalate to stronger sedatives as the algorithm.

ECT is not a panic treatment

Reserve ECT for severe mood/psychotic/catatonic indications — correct misconceptions calmly.
[1] [2] [3]

References

  1. [1]Barlow DH, Gorman JM, Shear MK, Woods SW Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial JAMA, 2000.PMID 10815116
  2. [2]Otto MW, Pollack MH, Sachs GS, et al. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder Am J Psychiatry, 1993.PMID 8379551
  3. [3]Pollack MH, Otto MW, Worthington JJ, et al. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial Arch Gen Psychiatry, 1998.PMID 9819070
  4. [4]Bandelow B, Michaelis S, Wedekind D Treatment of anxiety disorders Dialogues Clin Neurosci, 2017.PMID 28867934